‘Jardiance’ entering insurance benefit will expand SGLT-2 inhibitor market with Forxiga

Followed by AstraZeneca’s Forxiga and Astellas’s Suglat, Boehringer Ingelheim’s Jardiance entered the health insurance benefit door for the third time as a SGLT-2 inhibitor.

The last year’s prescriptions of Forxiga, exceeding KRW 10 billion, has brought a huge impact. The increase was explosive as inclined by 802% compared to the year before. This is because it controls not only blood sugar, b...